Search Result

Results for "

Wnt+pathway

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) AAK1 (1) AMPK (1) Apoptosis (3) Bacterial (1) c-Myc (1) Casein Kinase (1) CDK (2) COX (1) Creatine Kinase (1) Endogenous Metabolite (1) Fungal (1) GSK-3 (1) Histone Demethylase (1) mTOR (1) MyD88 (1) NF-κB (1) Notch (1) PARP (3) PASK/STK37 (1) Porcupine (2) Prostaglandin Receptor (2) Reactive Oxygen Species (ROS) (1) Reference Standards (3) Sirtuin (1) Smo (1) SOD (1) STAT (1) Toll-like Receptor (TLR) (1) Wnt (28) β-catenin (3)
By Research Areas:	Cancer (26) Cardiovascular Disease (4) Infection (1) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (2)

By Targets:

5-HT Receptor (1)

AAK1 (1)

AMPK (1)

Apoptosis (3)

Bacterial (1)

c-Myc (1)

Casein Kinase (1)

CDK (2)

COX (1)

Creatine Kinase (1)

Endogenous Metabolite (1)

Fungal (1)

GSK-3 (1)

Histone Demethylase (1)

mTOR (1)

MyD88 (1)

NF-κB (1)

Notch (1)

PARP (3)

PASK/STK37 (1)

Porcupine (2)

Prostaglandin Receptor (2)

Reactive Oxygen Species (ROS) (1)

Reference Standards (3)

Sirtuin (1)

Smo (1)

SOD (1)

STAT (1)

Toll-like Receptor (TLR) (1)

Wnt (28)

β-catenin (3)

By Research Areas:

Cancer (26)

Cardiovascular Disease (4)

Infection (1)

Inflammation/Immunology (3)

Metabolic Disease (2)

Neurological Disease (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-A0293

Pyrvinium pamoate Maximum Cited Publications 20 Publications Verification Pyrvinium embonate	Wnt	Cancer
Pyrvinium pamoate is an FDA-approved antihelmintic agent that inhibits *WNT* pathway signaling.

HY-106420

16,16-Dimethyl prostaglandin E2 16,16-dimethyl PGE2	Wnt Prostaglandin Receptor	Inflammation/Immunology
16,16-Dimethyl prostaglandin E2 (16,16-dimethyl PGE2) is an orally active vertebrate Hematopoietic stem cells (HSCs) homeostasis critical regulator. 16,16-Dimethyl prostaglandin E2 can act through EP2/EP4 and has an interaction with the Wnt pathway .

HY-12316

20(S)-Hydroxycholesterol 3 Publications Verification 20α-Hydroxycholesterol	Smo Endogenous Metabolite	Cardiovascular Disease Metabolic Disease Cancer
20(S)-Hydroxycholesterol (20α-Hydroxycholesterol) is an allosteric activator that selectively targets the Smoothened (Smo) of the Hedgehog pathway with an EC₅₀ of ~30 μM (Hedgehog). 20(S)-Hydroxycholesterol binds to the extracellular cysteine-rich domain (CRD) of Smo in a stereoselective manner, activating downstream Gli transcription factors (without inducing transcription of receptor genes in the Wnt pathway). 20(S)-Hydroxycholesterol enhances osteogenic differentiation of bone marrow stromal cells and synergistically activates the Raf/MEK/ERK pathway with Simvastatin (HY-17502) to promote bone regeneration. 20(S)-Hydroxycholesterol can be used to study the mechanisms of developmental biology, oncology, bone, and angiogenesis .

HY-123940

SGC-AAK1-1 1 Publications Verification	Wnt AAK1	Cancer
SGC-AAK1-1, a chemical probe, is a potent and selective AAK1 (AP2 associated kinase 1) inhibitor with an IC₅₀ of 270 nM and a K_i of 9 nM. SGC-AAK1-1 also potently inhibits BMP2K. SGC-AAK1-1 is used to study Wnt pathway related to AAK1 .

HY-P9974

Vantictumab 1 Publications Verification OMP-18R5	Wnt	Cancer
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits *Wnt* pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .

HY-135516

Dalosirvat 2 Publications Verification SM-04554; Wnt pathway activator 1	Wnt	Neurological Disease Metabolic Disease Cancer
Dalosirvat (SM-04554) is a potent Wnt activator with an EC₅₀s of 28-29 nM. Dalosirvat can be used in the study of cancer .

HY-N2896

Arjunolic acid	Reactive Oxygen Species (ROS) Apoptosis Fungal Bacterial NF-κB SOD AMPK mTOR Notch Toll-like Receptor (TLR) Wnt MyD88 Sirtuin	Infection Neurological Disease Inflammation/Immunology Cancer
Arjunolic acid is an orally active, multifunctional bioactive compound. Arjunolic acid exhibits free radical scavenging activity, as well as fungal and bacterial activities. Arjunolic acid induces apoptosis (Apoptosis) in various cancer cells. Arjunolic acid protects hepatocytes against induced oxidative stress and apoptosis by reducing reactive oxygen species and inhibiting NF-κB activation. Arjunolic acid regulates pancreatic dysfunction in type 2 diabetic rats by blocking the activation of the TLR-4/MyD88 and canonical *Wnt* pathways. Arjunolic acid inhibits neuroinflammation and ameliorates depressive behaviors via the SIRT1/AMPK/Notch1 signaling pathway in microglia. Arjunolic acid improves Crohn's disease-like colitis by restoring gut microbiota composition and inhibiting TLR4 signaling. Arjunolic acid suppresses osteosarcoma progression by inhibiting Wnt3a-mediated M2 polarization of macrophages. Arjunolic acid ameliorates diabetic retinopathy via the autophagy pathway regulated by AMPK/mTOR/HO-1. Arjunolic acid is applicable to research related to type 2 diabetes, organ toxicity, depression, Crohn's disease, osteosarcoma, diabetic retinopathy, and testicular dysfunction .

HY-121944

Ricinine	Casein Kinase Wnt	Others
Ricinine exhibits hepatoprotection in CCl4-induced liver damage. Ricinine is also a CK1α inhibitor, and may activate Wnt pathway .

HY-100408

GNF-6231	Wnt Porcupine	Cardiovascular Disease Cancer
GNF-6231 is a porcupine (IC₅₀= 0.8 nM), Pron, and endoplasmic reticulum protein inhibitor with oral activity. GNF-6231 has anticancer activity. GNF-6231 can prevent the activation of the Wnt pathway by blocking the secretion of all Wnt ligands. GNF-6231 can be used in the study of myocardial infarction .

HY-136541

YB-0158 2 Publications Verification Wnt pathway inhibitor 2	Wnt Apoptosis	Cancer
YB-0158 (Wnt pathway inhibitor 2) is a reverse-turn peptidomimetic and a potent colorectal cancer stem cell (CSC) targeting agent. YB-0158 disrupts Sam68-Src interactions and induces apoptosis in CRC cells. Anti-cancer activities .

HY-153750

Wnt pathway inhibitor 3	Wnt	Cancer
Wnt pathway inhibitor 3 is a potent wnt inhibitor with an IC₅₀ value of 45 nM. Wnt pathway inhibitor 3 shows antiproliferative activity .

HY-137443

Ipivivint 1 Publications Verification	CDK Wnt	Cancer
Ipivivint (Compound 38) is an orally active and potent CDC-like kinase (CLK) inhibitor with EC₅₀ of 1 nM and 7 nM for CLK2 (human) and CLK3 (human), respectively. Ipivivint also inhibits the Wnt pathway (EC50=13 nM) and tyrosine phosphorylation-regulated kinase 1A (human) (EC₅₀=5 nM) .

HY-151483

TK-129	Wnt Histone Demethylase	Cardiovascular Disease
TK-129 is an orally active, low-toxicity, potent KDM5B inhibitor (with high affinity; IC₅₀=44 nM). TK-129 exerts cardioprotective effects by inhibiting KDM5B and blocking the KDM5B-associated *Wnt* pathway. TK-129 reduces ang II-induced activation of cardiac fibroblasts in vitro and reduces isoprenaline-induced myocardial remodelling and fibrosis in vivo. TK-129 can be used in studies of cardiovascular disease .

HY-136073

Wnt pathway activator 2	Wnt	Cancer
Wnt pathway activator 2 (compound 2) is a potent Wnt activator with an EC₅₀ of 13 nM .

HY-126248

Tankyrase-IN-2	PARP Wnt	Cancer
Tankyrase-IN-2 (compound 5k) is a potent, selective, and orally active tankyrase inhibitor (IC₅₀s of 10, 7, and 710 nM for TNKS1, TNKS2 as well as PARP1, respectively). Tankyrase-IN-2 has favorable physicochemical profile and pharmacokinetic properties modulating Wnt pathway activity in a colorectal xenograft model .

HY-169730

Wnt pathway inhibitor 5	Wnt	Cancer
Wnt pathway inhibitor 5 (Compound 28) is *wnt pathway* inhibitor, with an IC₅₀ value of < 0.003 μΜ. Wnt pathway inhibitor 5 inhibits many cancers, including ovarian teratocarcinoma cancer, breast cancer, osteosarcoma, head and neck squamous carcinoma .

HY-153753

Wnt pathway inhibitor 4	Wnt	Cancer
Wnt pathway inhibitor 4 (compound 16D) is an anticancer agent that has anti-proliferative activity .

HY-A0293R

Pyrvinium pamoate (Standard) Pyrvinium embonate (Standard)	Reference Standards Wnt	Cancer
Pyrvinium pamoate (Standard) is the analytical standard of Pyrvinium pamoate. This product is intended for research and analytical applications. Pyrvinium pamoate is an FDA-approved antihelmintic agent that inhibits *WNT* pathway signaling.

HY-49597

Pin1 modulator 1	Wnt β-catenin	Cancer
Pin1 modulator 1 (compound IIb-219) is a modulator that specifically targets β-Catenin and inhibits the *Wnt* pathway. Pin1 modulator 1 can be used in the study of Wnt-mediated related diseases, such as cancer .

HY-P10652

hsBCL9CT-24	Wnt β-catenin	Cancer
hsBCL9CT-24 is a Wnt/β-catenin (b-cat) pathway inhibitor with potent anti-tumor effect. hsBCL9CT-24 reactivates anti-cancer immune response suppressed by the oncogenic Wnt pathway and can be utilized for cancer research .

HY-108516

TC-E 5001	Wnt PARP	Cancer
TC-E 5001 is an inhibitor of *Wnt pathway* that inhibits tankyrase 1/2 (TNKS1/2) via novel adenosine pocket binding, with K_ds of 79 nM and 28 nM, respectively. TC-E 5001 also inhibits Axin2 and STF, with IC₅₀s of 0.709 μM and 0.215 μM, respectively .

HY-19972

ML243	Wnt	Cancer
ML243 is a selective small-molecule inhibitor of breast cancer stem cells. ML243 has 32-fold greater selective inhibition in the breast CSC-like cell line HMLE_shECad than the control cell line HMLE_shGFP. ML243 may target the *Wnt* pathway at the protein level without altering RNA expression levels .

HY-120864

SEN461	Wnt	Cancer
SEN461 is a potent and orally active *Wnt pathway* inhibitor. SEN461 shows effective anti-tumor activity and can be used for GBM research .

HY-129284

APHS	COX Wnt	Cancer
APHS is a specific and covalent COX-2 inhibitor with neuroprotective effects. COX-2 is a prostaglandin (PG) synthetase overexpressed in colorectal cancer (CRC) and has pleiotropic cancer-promoting effects. APHS modifies COX-2 by acetylating the active site (serine 516), thereby inhibiting prostaglandin production. The neuroprotective activity of APHS is inhibited by prostaglandin E2. APHS also co-inhibits the WNT pathway, an anti-tumor mechanism in addition to COX-2 inhibition .

HY-172747

TNKS-2-IN-3	PARP	Cancer
TNKS-2-IN-3 (Compound 5) is a selective competitive tankyrase 2 (TNKS2) inhibitor with an IC₅₀ value of 0.3 nM, showing over 20-fold selectivity over TNKS1 and more than 100-fold selectivity over PARP1/2. TNKS-2-IN-3 stabilizes axin and suppresses the Wnt/β-catenin pathway by inhibiting TNKS2-mediated ADP-ribosylation, exhibiting antiproliferative activity in colorectal cancer cells. TNKS-2-IN-3 is proming for rasearch of solid tumors with aberrant Wnt pathway activation, such as colorectal cancer .

HY-181584

AKI-062a	GSK-3 Creatine Kinase	Others
AKI-062a is a non-selective kinase inhibitor, such as a CK1γ inhibitor. AKI-062a binds to and inhibits WNT pathway kinases and GSK3β. At a concentration of 1 μM, AKI-062a binds to 17 kinases, with a binding activity of <10% of that of the control group .

HY-100408R

GNF-6231 (Standard)	Wnt Porcupine Reference Standards	Cardiovascular Disease Cancer
GNF-6231 (Standard) is the analytical standard of GNF-6231 (HY-100408). This product is intended for research and analytical applications. GNF-6231 is a porcupine (IC50= 0.8 nM), Pron, and endoplasmic reticulum protein inhibitor with oral activity. GNF-6231 has anticancer activity. GNF-6231 can prevent the activation of the Wnt pathway by blocking the secretion of all Wnt ligands. GNF-6231 can be used in the study of myocardial infarction .

HY-181930

TNIK-IN-10	Wnt c-Myc Apoptosis	Cancer
TNIK-IN-10 (Compound N15) is a TNIK inhibitor with an IC₅₀ of 0.49 nM against human TNIK. TNIK-IN-10 inhibits the enzymatic activity of TNIK, downregulates the expression of *Wnt* pathway target genes c-Myc and AXIN2, and reduces the protein expression of LRP5 and LRP6. TNIK-IN-10 induces apoptosis. TNIK-IN-10 exhibits anticancer activity against colorectal cancer. TNIK-IN-10 can be used in the research of colorectal cancer .

HY-114178

CDK8-IN-2	CDK STAT Wnt 5-HT Receptor PASK/STK37	Cancer
CDK8-IN-2 is an orally active CDK8 inhibitor of an IC₅₀ values of 0.010 μM. CDK8-IN-2 shows a CDK19 IC₅₀ value of 0.026 μM. CDK8-IN-2 inhibits phospho-STAT1, a pharmacodynamic biomarker of CDK8. CDK8-IN-2 inhibits WNT pathway activity. CDK8-IN-2 can be used for the research of colorectal carcinoma .

HY-106420R

16,16-Dimethyl prostaglandin E2 (Standard) 16,16-dimethyl PGE2 (Standard)	Wnt Reference Standards Prostaglandin Receptor	Inflammation/Immunology
16,16-Dimethyl prostaglandin E2 (Standard) is the analytical standard of 16,16-Dimethyl prostaglandin E2 (HY-106420). This product is intended for research and analytical applications. 16,16-Dimethyl prostaglandin E2 (16,16-dimethyl PGE2) is an orally active vertebrate Hematopoietic stem cells (HSCs) homeostasis critical regulator. 16,16-Dimethyl prostaglandin E2 can act through EP2/EP4 and has an interaction with the Wnt pathway .

HY-165503

AZ1366	Wnt β-catenin	Cancer
AZ1366 is an orally active tankyrase inhibitor. AZ1366 stabilizes Axin2, reduces NuMA levels, disrupts the interaction between tankyrase and NuMA, induces G2/M phase arrest, inhibits the *Wnt* pathway, and downregulates the expression of β-catenin-dependent genes. AZ1366 inhibits tumor growth in colorectal cancer xenograft models. AZ1366 synergistically inhibits the proliferation of non-small cell lung cancer cells, improves tumor control and significantly prolongs survival in orthotopic non-small cell lung cancer mouse models. AZ1366 is applicable to research related to colorectal cancer and non-small cell lung cancer .

Cat. No.	Product Name	Target	Research Area